BioSpace News Archive

Lone Star Bio

atsec AB first IEEE 2621 Accredited Medical Device Testing Facility

atsec AB Stockholm, Sweden is thrilled to announce: We are the first IEEE Authorized Testing Facility! This press release features multimedia.

April 3, 2024
·
2 min read
Business

Opthea Appoints Sujal Shah to the Board of Directors

Opthea Limited, a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, announced the appointment of Sujal Shah to the Company’s Board of Directors, effective April 4, 2024.

April 3, 2024
·
8 min read
Policy

IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

IASO Biotechnology is pleased to announce that the Investigational New Drug application for its BCMA CAR-T has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for generalised myasthenia gravis.

April 3, 2024
·
5 min read
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

Eupraxia Pharmaceuticals Inc. announced that the Company’s common shares have been approved for listing on the Nasdaq Capital Market.

April 3, 2024
·
5 min read
flexFS: A File System Transforming the Efficiency of Large-scale Cloud Analytics in Life Sciences and Beyond

Launched in 2023 to address the needs of biopharma R&D teams querying vast multimodal datasets simultaneously, flexFS’s cloud-agnostic, infinitely elastic and POSIX-compliant profile has since also proven its value in other data-intensive fields, including climate science and insurance risk modeling.

April 3, 2024
·
4 min read
Business

Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results

Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024.

April 3, 2024
·
15 min read
Biotech Beach

Palisade Bio Announces 1-for-15 Reverse Stock Split

Palisade Bio, Inc. announced a 1-for-15 reverse split of its common stock, par value $0.01, effective at 5:00 PM ET on Friday April 5, 2024.

April 3, 2024
·
4 min read
Business

Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, reported financial results for the fourth quarter and full year ended 2023 and provided a corporate update.

April 3, 2024
·
10 min read
Policy

Acorda Therapeutics Announces Nasdaq Delisting Notification

Acorda Therapeutics, Inc. announced that Nasdaq Stock Market notified the Company that it will suspend trading in and delist the Company’s common stock, effective with the opening of business on April 12, 2024.

April 3, 2024
·
6 min read
Policy

Partner Therapeutics’ Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Partner Therapeutics, Inc. announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency for the inhaled use of Leukine, branded in Japan as Sargmalin, to treat aPAP.

April 3, 2024
·
8 min read